Fox N C, Scahill R I, Crum W R, Rossor M N
Department of Clinical Neurology, Institute of Neurology, University College, London, UK.
Neurology. 1999 May 12;52(8):1687-9. doi: 10.1212/wnl.52.8.1687.
Twenty-nine untreated patients diagnosed with probable AD and 15 control patients underwent two or more clinical and volumetric MRI assessments with intervals ranging from 5 months to 6 years. The change in global cerebral volume for an individual was calculated by a novel method of registration and subtraction of serial scans. Rate of global cerebral volume loss correlated strongly with rate of change in Mini-Mental State Examination scores (r = 0.80, p < 0.001), implying clinical relevance to this marker of progression.
29名被诊断为可能患有阿尔茨海默病(AD)的未接受治疗的患者和15名对照患者接受了两次或更多次临床和容积MRI评估,评估间隔时间为5个月至6年。个体的全脑体积变化通过一种新的序列扫描配准和减法方法进行计算。全脑体积损失率与简易精神状态检查表评分的变化率密切相关(r = 0.80,p < 0.001),这意味着该进展标志物具有临床相关性。